NCT03769896View on ClinicalTrials.gov

Nabilone for Non-motor Symptoms in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 3, 2017

Primary Completion Date

July 15, 2019

Study Completion Date

July 15, 2019

Conditions
Parkinson Disease
Interventions
DRUG

Nabilone 0.25 mg

capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis

DRUG

Placebo

capsule, corn starch, daily basis

Trial Locations (1)

6020

Department of Neurology - Medical University Innsbruck, Innsbruck

All Listed Sponsors
lead

Medical University Innsbruck

OTHER

NCT03769896 - Nabilone for Non-motor Symptoms in Parkinson's Disease | Biotech Hunter | Biotech Hunter